1. Exposure to Rosiglitazone and Fluoxetine in the First Trimester of Pregnancy
- Author
-
Jung-Yeol Han, Mi-Kyoung Koong, Joong-Sik Shin, Jae-Hyug Yang, Alejandro A Nava-Ocampo, Hyun-Kyong Ahn, and June Seek Choi
- Subjects
Advanced and Specialized Nursing ,medicine.medical_specialty ,Pregnancy ,medicine.drug_class ,business.industry ,Endocrinology, Diabetes and Metabolism ,Atorvastatin ,Pipenzolate bromide ,medicine.disease ,Polycystic ovary ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,Internal Medicine ,medicine ,Spironolactone ,Thiazolidinedione ,business ,Rosiglitazone ,Acarbose ,medicine.drug - Abstract
Rosiglitazone is a thiazolidinedione oral hypoglycemic drug that seems to be a promising alternative not only as an oral hypoglycemic agent but also for women with polycystic ovary syndrome. However, information regarding exposure to rosiglitazone in pregnancy is limited to two previous case reports. In the first case, a 35-year-old woman was exposed until the 8th week of pregnancy to 4 mg/day rosiglitazone and to glicazide, acarbose, atorvastatin, spironolactone, hydrochlorothiazide, carbamazepine, thiridazine, amitryptiline, chlordiazepoxide, and pipenzolate bromide (1). The second case was a woman exposed to 4 mg/day rosiglitazone between gestational weeks 13 and 17 (2). The two cases delivered normal babies at gestational weeks 36 and 37, …
- Published
- 2006
- Full Text
- View/download PDF